RT Journal Article
SR Electronic
T1 UBR1 Promotes Sex-Dependent ACE2 Ubiquitination in Hypertension
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.23.24307722
DO 10.1101/2024.05.23.24307722
A1 Elgazzaz, Mona
A1 Lakkappa, Navya
A1 Berdasco, Clara
A1 Mohan, Uma Priya
A1 Nuzzo, Anna
A1 Restivo, Luke
A1 Martinez, Alexa
A1 Scarborough, Amy
A1 Guidry, Jessie J.
A1 Sriramula, Srinivas
A1 Xu, Jiaxi
A1 Daoud, Hisham
A1 Mendiola Plá, Michelle A.
A1 Bowles, Dawn E.
A1 Beyer, Andreas M.
A1 Mauvais-Jarvis, Franck
A1 Yue, Xinping
A1 Filipeanu, Catalin M.
A1 Lazartigues, Eric
YR 2024
UL http://medrxiv.org/content/early/2024/05/25/2024.05.23.24307722.abstract
AB Background Angiotensin (Ang)-II impairs the function of the antihypertensive enzyme ACE2 by promoting its internalization, ubiquitination and degradation thus contributing to hypertension. However, few ACE2 ubiquitination partners have been identified and their role in hypertension remains unknown.Methods Proteomics and bioinformatic analysis were used to identify ACE2 ubiquitination partners in the brain, heart, and kidney from Ang-II-infused C57BL6/J mice from both sexes and validated the interaction between UBR1 and ACE2 in cells. Central and peripheral UBR1 knockdown was then performed in male mice to investigate its role in the maintenance of hypertension.Results Proteomics analysis from hypothalamus identified UBR1 as a potential E3 ligase promoting ACE2 ubiquitination. Enhanced UBR1 expression, associated with ACE2 reduction, was confirmed in various tissues from hypertensive male mice and human samples. Treatment of endothelial and smooth muscle cells with testosterone, but not 17β-estradiol, confirmed a sex-specific regulation of UBR1. In vivo silencing of UBR1 using chronic administration of small interference RNA resulted in the restoration of ACE2 levels in hypertensive males. A transient decrease in blood pressure following intracerebroventricular, but not systemic, infusion was also observed. Interestingly, UBR1 knockdown increased the brain activation of Nedd4-2, an E3 ligase promoting ACE2 ubiquitination and reduced expression of SGK1, the kinase inactivating Nedd4-2. Conclusions: These data demonstrate that UBR1 is a novel ubiquitin ligase targeting ACE2 in hypertension. UBR1 and Nedd4-2 E3 ligases appear to work synergistically to ubiquitinate ACE2. Targeting of these ubiquitin ligases may represent a novel strategy to restore ACE2 compensatory activity in hypertension.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by research grants from the National Institutes of Health (HL150592 to E.L. and C.M.F. and CoBRE P30GM106392), the United States Department of Veterans Affairs (Biomedical Laboratory Research and Development Service, Merit Award I01 BX004294), and the Research Enhancement Program at LSU Health-NOAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cardiac samples from patients were obtained from The Medical College of Wisconsin (IRB #PRO00010828) and Duke University (IRB #PRO00005621) from organs not suitable for transplant. Informed consents were obtained prior to experiments and all procedures conform to the principles outlined in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available at the time of publication.ACE2Angiotensin Converting Enzyme 2Ang-IIAngiotensin IIAng-(1-7)Angiotensin (1-7)ANOVAAnalysis of varianceAT1RAng-II type 1 receptorBPBlood pressureDHTdihydrotestosteroneDBDiandrogen receptor (AR) DNA-binding domain inhibitorE1Ubiquitin-activating enzymesE2Ubiquitin-conjugating enzymesE3Ubiquitin protein ligasesENaCKidney epithelial Na+ channelsHAECHuman aortic endothelial cellsLC-MSLiquid chromatography–mass spectrometryMAPMean arterial pressureMDM2Murine double minute 2MPPMethylpiperidinopyrazoleNedd4-2Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 4PHTPP4-[2-PHENYL-5,7-BIS(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]PHENOLRASRenin-angiotensin systemSkp2S-Phase Kinase Associated Protein 2siRNASmall interfering RNASMCSmooth muscle cellSGK1Serum/Glucocorticoid-Regulated Kinase 1UBR1Ubiquitin Protein Ligase E3 Component N-Recognin